enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company, has announced that Ron Cooper, the company's President and CEO, will engage in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026. This event is scheduled for Wednesday, February 11, 2026, at 2:30 p.m. ET. Interested parties can access a live webcast of the discussion on the “Events and Presentations” section of enGene's website, where it will also be archived for 90 days for later viewing.

enGene is committed to advancing genetic medicine via non-viral methodologies, focusing particularly on the therapeutic delivery to mucosal tissues and other organs. The company’s primary initiative is the development of detalimogene voraplasmid, specifically targeting Non-Muscle Invasive Bladder Cancer (NMIBC), a condition characterized by significant clinical challenges. The drug is currently under evaluation in the LEGEND Phase 2 trial, which consists of multiple cohorts, including pivotal assessments for high-risk patients who are unresponsive to Bacillus Calmette-Guérin (BCG) treatment.

Detalimogene was formulated using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform, which facilitates robust mucosal penetration and allows for the delivery of diverse therapeutic agents, such as DNA and RNA in various forms. By focusing on unmet clinical needs, enGene aims to revolutionize treatment methodologies and improve patient outcomes. For further details, stakeholders are encouraged to visit enGene’s website and follow the company on social media platforms including LinkedIn, X, and BlueSky.

For media inquiries, contact media@engene.com, and for investor contacts, reach out to investors@engene.com.

As enGene Holdings Inc. (Nasdaq: ENGN) prepares for its participation in the Guggenheim Emerging Outlook: Biotech Summit 2026, investors should closely monitor the developments surrounding the company and its pipeline, particularly its lead program, detalimogene voraplasmid. This clinical-stage biotechnology firm focuses on advancing genetic medicines, especially its innovative delivery methods targeting mucosal tissues, a strategy that sets it apart in the competitive biotech landscape.

The upcoming fireside chat featuring CEO Ron Cooper provides a unique platform for enGene to articulate its vision and progress, specifically regarding the ongoing LEGEND Phase 2 trial for NMIBC. This indication is particularly noteworthy, as NMIBC presents a significant clinical burden and lacks adequate treatment options for patients who are BCG-unresponsive. As the trial progresses and more data becomes available, this could catalyze interest from both institutional and retail investors.

Additionally, the proprietary DDX platform enhances enGene’s potential by allowing diverse therapeutic candidates to be delivered efficiently to challenging tissue types. This positions enGene not only as a contender in bladder cancer but potentially across various diseases treated with genetic therapies.

Investors should view the summit participation as an opportunity to gauge market sentiment and obtain critical updates that may impact the stock's future performance. Anticipate enhanced visibility and discussion around financing, partnership opportunities, and the company's long-term strategy, which could influence stock valuation.

In summary, while enGene represents potential high risk, its innovative approach and focus on unmet medical needs in the oncology space could offer significant upside. Keeping abreast of developments from the summit and the LEGEND trial will be crucial for making informed investment decisions.